In the third quarter, HeartWare International (NASDAQ:HTWR) had better than expected sales of its cardiac pumps and as a result, its share price moved up substantially.
The jump in sales was driven by the widespread acceptance of HeartWare's HVADs (ventricular assist device), particularly in foreign markets, in line with predictions made at the time the device was launched in the U.S. a year ago.
Some predict now that HeartWare is destined to take over the leadership of the heart pump industry in the next few years from current leader, Thoratec (NASDAQ:THOR).
The company is still losing money, although the loss has narrowed to $11.4 million from $25.0 million a year ago.
In December HeartWare bought CircuLite...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|